Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
A Tefferi - American journal of hematology, 2016 - Wiley Online Library
Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …
[HTML][HTML] Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
JC Bryan, S Verstovsek - Cancer chemotherapy and pharmacology, 2016 - Springer
Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative
neoplasms associated with somatic hematopoietic stem cell mutations leading to over …
neoplasms associated with somatic hematopoietic stem cell mutations leading to over …
Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …
Acute megakaryocytic leukemia: What have we learned
Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute
myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of …
myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of …
A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms
J Mascarenhas - Clinical Lymphoma Myeloma and Leukemia, 2016 - Elsevier
Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold
a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape …
a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape …
[HTML][HTML] Outcome of allogeneic hematopoietic stem cell transplantation for patients with chronic and advanced phase myelofibrosis
Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …
Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review
N Farhadfar, S Cerquozzi, M Patnaik… - Journal of oncology …, 2016 - ascopubs.org
Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary
hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in …
hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in …
The evolution and clinical relevance of prognostic classification systems in myelofibrosis
P Bose, S Verstovsek - Cancer, 2016 - Wiley Online Library
Primary myelofibrosis, the most aggressive of the classic Philadelphia chromosome‐
negative myeloproliferative neoplasms (MPNs), is a clonal disorder characterized by often …
negative myeloproliferative neoplasms (MPNs), is a clonal disorder characterized by often …
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms.
R Devillier, E Raffoux, J Rey… - British Journal of …, 2016 - search.ebscohost.com
The article reports a bi-centric experience of six patients who received ruxolitinib in
combination with intensive chemotherapy for myeloproliferative neoplasms in blast-phase …
combination with intensive chemotherapy for myeloproliferative neoplasms in blast-phase …
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
AL Sochacki, MA Fischer, MR Savona - OncoTargets and therapy, 2016 - Taylor & Francis
The discovery of JAK2 V617F a decade ago led to optimism for a rapidly developing
treatment revolution in Ph− myeloproliferative neoplasms. Unlike BCR–ABL, however, JAK2 …
treatment revolution in Ph− myeloproliferative neoplasms. Unlike BCR–ABL, however, JAK2 …